Boston Scientific won the CE Mark for the X4 line of resynchronization therapy defibrillators (CRT-Ds) that interface with ACUITY X4 quadripolar leads that feature a variety of electrode spacing configurations to best match each patient’s unique heart anatomy. The ACUITY X4 have the narrowest tip among all quadripolar leads available and can be positioned using the ACUITY PRO delivery system through vessels that may otherwise not support a wider device.
The X4 line of CRT-Ds includes the AUTOGEN X4, DYNAGEN X4, and INOGEN X4.
“The unique design of the ACUITY X4 lead allows me to pace from more optimal locations while enabling excellent stability of the lead, low battery consumption and avoiding phrenic nerve stimulation, which are all important issues for CRT patients,” said Prof. Curnis. “Thanks to the 17 pacing vector options, it is possible to manage micro dislodgments of the lead and optimize pacing threshold without additional procedures, drastically reducing the risk to patients. This, along with Boston Scientific’s outstanding battery technology, delivers a CRT-D system that truly benefits patients over the long term.”
The X4 line of quadripolar CRT-Ds offers the largest number of pacing vector options in the industry and helps physicians effectively address high-pacing capture thresholds and phrenic nerve stimulation, a common complication of CRT therapy due to close proximity of the phrenic nerve to the desired pacing location in the left ventricle. The X4 CRT-Ds also feature Boston Scientific’s 6-year warranty and industry-leading longevity. An independent, single-center, observational study of 646 CRT-D recipients (n= 173 BSX, 416 MDT, 57 SJM devices) implanted between January 1, 2008 and December 31, 2010 recently published in the United States showed that during 2.7+/-1.5 years follow-up, only four percent of Boston Scientific device batteries had depleted, compared to seven percent from St. Jude Medical and 25 percent from Medtronic.[iii] X4 CRT-Ds utilize the same, industry-leading battery capacity and advanced battery chemistry as the Boston Scientific devices used in this study.
Press release: Boston Scientific Announces CE Mark Approval And First Implants Of Its Next-Generation X4 Quadripolar CRT-D Systems…
